Lei Gong1,2, Xuyang Wang1, Jinyu Pan1, Mingjun Zhang1, Dian Liu1, Ming Liu1, Li Li2, Fengshuang An1. 1. The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, No. 107 WenHuaXi Road, Jinan, Shandong 250012, China. 2. The Second Affiliated Hospital of Xuzhou Medical University, No.32 MeiJian Road, Quanshan District, Xuzhou, Jiangsu 221000, China.
Abstract
OBJECTIVE: The purpose of the present study was to evaluate the role of co-treatment of rosuvastatin (RSV) and dapagliflozin (DGZ) preconditioning in myocardium ischemia/reperfusion (I/R) injury and to further investigate the underlying mechanism. METHODS: Sprague-Dawley (SD) rats (n = 25) were divided into five groups randomly: (1) Sham, (2) I/R, (3) I/R + RSV (10 mg/kg), (4) IR + DGZ (1 mg/kg), and (5) I/R + RSV (10 mg/kg) + DGZ (1 mg/kg). The I/R model was induced with 30 min of left anterior descending occlusion followed by 120 min of reperfusion. RESULTS: In vivo pretreatment with RSV and DGZ, respectively, showed a significant reduction of infarction size, a significant increase in the levels of left ventricular systolic pressure, and maximal rate increase in left ventricular pressure (+dp/dt max), decrease in the levels of left ventricular end-diastolic pressure (LVEDP), maximal rate of decrease of left ventricular pressure (-dp/dt max) and activity of cardiac enzymes of creatine kinase (CK), creatine kinase MB isoenzymes (CK-MB), and hyper-tensive cardiac troponin I compared with the I/R group. H9C2 cells were exposed to hypoxia/reoxygenation to simulate an I/R model. In vitro administration of 25 µM RSV and 50 µM DGZ significantly enhanced cell viability, upregulated the expression levels of p-PI3K, p-Akt, p-mTOR, and Bcl-2, whereas it downregulated cleaved-caspase3, Bax. TUNEL assay indicated that pretreatment with RSV and DGZ decreased the apoptosis of H9C2 cells. CONCLUSION: The combination of RSV and DGZ significantly enhances the cardioprotective effects compared with RSV or DGZ alone. RSV and DGZ have the potential cardioprotective effects against I/R injury by activating the PI3K/AKt/mTOR signaling pathway.
OBJECTIVE: The purpose of the present study was to evaluate the role of co-treatment of rosuvastatin (RSV) and dapagliflozin (DGZ) preconditioning in myocardium ischemia/reperfusion (I/R) injury and to further investigate the underlying mechanism. METHODS: Sprague-Dawley (SD) rats (n = 25) were divided into five groups randomly: (1) Sham, (2) I/R, (3) I/R + RSV (10 mg/kg), (4) IR + DGZ (1 mg/kg), and (5) I/R + RSV (10 mg/kg) + DGZ (1 mg/kg). The I/R model was induced with 30 min of left anterior descending occlusion followed by 120 min of reperfusion. RESULTS: In vivo pretreatment with RSV and DGZ, respectively, showed a significant reduction of infarction size, a significant increase in the levels of left ventricular systolic pressure, and maximal rate increase in left ventricular pressure (+dp/dt max), decrease in the levels of left ventricular end-diastolic pressure (LVEDP), maximal rate of decrease of left ventricular pressure (-dp/dt max) and activity of cardiac enzymes of creatine kinase (CK), creatine kinase MB isoenzymes (CK-MB), and hyper-tensive cardiac troponin I compared with the I/R group. H9C2 cells were exposed to hypoxia/reoxygenation to simulate an I/R model. In vitro administration of 25 µM RSV and 50 µM DGZ significantly enhanced cell viability, upregulated the expression levels of p-PI3K, p-Akt, p-mTOR, and Bcl-2, whereas it downregulated cleaved-caspase3, Bax. TUNEL assay indicated that pretreatment with RSV and DGZ decreased the apoptosis of H9C2 cells. CONCLUSION: The combination of RSV and DGZ significantly enhances the cardioprotective effects compared with RSV or DGZ alone. RSV and DGZ have the potential cardioprotective effects against I/R injury by activating the PI3K/AKt/mTOR signaling pathway.
Authors: Kristian Thygesen; Johannes Mair; Evangelos Giannitsis; Christian Mueller; Bertil Lindahl; Stefan Blankenberg; Kurt Huber; Mario Plebani; Luigi M Biasucci; Marco Tubaro; Paul Collinson; Per Venge; Yonathan Hasin; Marcello Galvani; Wolfgang Koenig; Christian Hamm; Joseph S Alpert; Hugo Katus; Allan S Jaffe Journal: Eur Heart J Date: 2012-06-21 Impact factor: 29.983
Authors: Fred S Apple; Allan S Jaffe; Paul Collinson; Martin Mockel; Jordi Ordonez-Llanos; Bertil Lindahl; Judd Hollander; Mario Plebani; Martin Than; M H M Chan Journal: Clin Biochem Date: 2014-09-07 Impact factor: 3.281
Authors: Jing Li; Xi Li; Qing Wang; Shuang Hu; Yongfei Wang; Frederick A Masoudi; John A Spertus; Harlan M Krumholz; Lixin Jiang Journal: Lancet Date: 2014-06-23 Impact factor: 79.321
Authors: Fernando A C Seara; Leonardo Maciel; Raiana A Q Barbosa; Nayana C Rodrigues; Anderson L B Silveira; Michelle P Marassi; Adriana B Carvalho; José Hamilton M Nascimento; Emerson L Olivares Journal: PLoS One Date: 2018-01-05 Impact factor: 3.240
Authors: Wenchi Guan; Arjun K Venkatesh; Xueke Bai; Si Xuan; Jing Li; Xi Li; Haibo Zhang; Xin Zheng; Frederick A Masoudi; John A Spertus; Harlan M Krumholz; Lixin Jiang Journal: Eur Heart J Qual Care Clin Outcomes Date: 2019-01-01